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Abstract
Late-onset Alzheimer’s disease (LOAD) is a multifactorial disorder with over twenty loci associated with disease risk. Given
the number of genome-wide significant variants that fall outside of coding regions, it is possible that some of these variants
alter some function of gene expression rather than tagging coding variants that alter protein structure and/or function.
RegulomeDB is a database that annotates regulatory functions of genetic variants. In this study, we utilized RegulomeDB to
investigate potential regulatory functions of lead single nucleotide polymorphisms (SNPs) identified in five genome-wide
association studies (GWAS) of risk and age-at onset (AAO) of LOAD, as well as SNPs in LD (r2$0.80) with the lead GWAS
SNPs. Of a total 614 SNPs examined, 394 returned RegulomeDB scores of 1–6. Of those 394 variants, 34 showed strong
evidence of regulatory function (RegulomeDB score ,3), and only 3 of them were genome-wide significant SNPs (ZCWPW1/
rs1476679, CLU/rs1532278 and ABCA7/rs3764650). This study further supports the assumption that some of the non-coding
GWAS SNPs are true associations rather than tagged associations and demonstrates the application of RegulomeDB to
GWAS data.
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Introduction
Over 1200 genome-wide association studies (GWAS) have been
published since 2005 [1]. While some of these studies have been
crucial for determining genes responsible for disease phenotypes,
including determination of genes involved in inflammatory bowel
disease and age-related macular degeneration, the majority of
variants identified show modest effect size at best. Furthermore,
88% of significant variants are located in either intronic or
intergenic regions that do not encode proteins, suggesting their
association with disease may occur for reasons other than changes
in protein structure and/or function [2].
Given these findings, researchers recently have begun to
deliberate implications of these non-coding variants. One such
consideration is the possibility that, splice site variants and
promoters aside, introns and intergenic regions are not ‘‘junk
DNA’’ as previously believed, but possess regulatory properties
which modify gene expression. Indeed, only 2% of the human
genome encodes proteins, the remaining 98% is not ‘‘functional’’
in the sense that it does not encode proteins. Rather, the bulk of
the genome is comprised of repeat regions, introns, and
transposons [3]. Multiple molecular techniques have been
employed to determine chromatin structure, methylation, and
protein motifs and binding to assess the effect of non-coding
variants on transcription [4]. RegulomeDB is a database
developed to capture these data, and subsequently, assess the
likelihood that a particular variant affects transcription factor
binding. The advent of such databases is advantageous for
studying gene associations of complex diseases [2].
Late-onset Alzheimer’s disease (LOAD) is one such disease that
may be better understood by examining the regulatory function of
associated SNPs. Thus far, genome-wide association studies
(GWAS) of LOAD have identified over 20 significantly associated
risk loci [5–7]. In addition, several suggestive loci for risk and age-
at-onset (AAO) of AD have also been implicated [8], [9]. Of these
loci, only one, APOE, shows a strong effect size, which substantially
increases risk for individuals homozygous for the APOE*4 allele
especially after age 75 [10], [11]. The remaining loci have only
weak to modest effect sizes. In this study, we have demonstrated
the utility of two publicly available bioinformatics tools, Broad
Institute’s SNP Annotation and Proxy search (SNAP) tool (http://
www.broadinstitute.org/mpg/snap/) [12] and RegulomeDB
(http://regulomedb.org) [2], to investigate potential regulatory
functions of recently identified, non-APOE variants (index and
proxy SNPs) for known and suggestive loci associated with risk and
AAO of LOAD.
Methods
SNP selection
We selected a total of 44 genome-wide significant or suggestive
single-nucleotide polymorphisms (SNPs) reported for risk or AAO
of AD (see Table S1). Included among these SNPs were the 28
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genome-wide significant SNPs from 21 non-APOE LOAD risk loci
(PICALM, BIN1, CD33, CD2AP, MS4A4A/MS4A6E, ABCA7,
EPHA1, CLU, CR1, HLA-DRB5/HLA-DRB1, PTK2B, SORL1,
SLC24A4/RIN3, DSG2, INPP5D, MEF2C, NME8, ZCWPW1,
CELF1, FERMT2, and CASS4) [5-7] and 16 SNPs from novel
suggestive loci identified in two GWAS of risk and AAO of LOAD
(DCHS, HRK/RNFT2, ADAMTS9, KCNV2/VLDLR, LEMD2/
MLN/MIR1275, LOC390958/Sec11C, ZNF592/ALPK3/SLC28A1,
PSMD1/HTR2B/ARMC9, NRXN3, PPP1R3B, MMP3/MMP12,
FLJ37543, PCDH7, LOC440390, MAPRE1P2 pseudogene, and
PP1R2P5 pseudogene) [8], [9]. IRB approval and informed
consent procedures were outlined in each of the publications from
which SNPs were selected [5-9].
Linkage Disequilibrium
Following SNP selection, we utilized the SNAP web portal
[accessed 4 September 2013] [12] to identify SNPs in linkage
disequilibrium (LD) (r2$0.80) with our SNPs of interest. SNAP
allows users to find proxy SNPs based upon LD determined using
the CEU populations from the International HapMap (v3) or 1000
Genomes Pilot 1 projects. SNAP searches were not limited by
array and the identified SNPs could include the queried SNPs as
proxies for themselves. At r2$0.80, the SNAP portal found 570
SNPs in LD with the 44 GWAS SNPs. SNAP proxy searches were
repeated with r2 thresholds of 0.90 and 1.0 to better assess
associations among related SNPs. These higher thresholds yielded
a total of 472 and 191 identified SNPs, respectively. As expected,
the number of identified SNPs in LD with the 44 published SNPs
decreased as the r2 threshold increased. Table 1 summarizes the
total number of SNPs in LD at all three thresholds for both
HapMap3 and 1000 Genomes searches. All published SNPs and
their respective proxy SNPs for each r2 threshold are listed in
Table S1.
RegulomeDB
RegulomeDB is a database providing functional annotation of
SNPs as determined by data from the ENCODE Project
Consortium (2012), NCBI Sequence Read Archive, and other
sources totaling 962 data sets. It is free and publicly accessible
(http://www.regulomedb.org) and has a straight-forward inter-
face. With almost 60 million annotations, this tool will be
invaluable for future examination of gene expression and disease
traits. Variants can be classified into one of four RegulomeDB
categories with scores ranging from 1 to 6 indicating putative
functions. Scores and corresponding functional evidence are listed
in Table 2. All reported SNPs and SNPs in LD (using the r2$0.80
list) were examined for potential regulatory functions using
RegulomeDB (http://regulomedb.org, accessed [4 September
2013]) [2].
Results
Of the 614 SNPs examined in RegulomeDB, 220 had
RegulomeDB scores of ‘‘No Data’’, and the remaining 394
returned scores of 1–6. Of those 394 variants, 34 had a
RegulomeDB score of less than 3 (Table 3 and Table S2),
indicating a relatively high degree of evidence for potential
regulatory function (‘‘likely to affect binding’’). Interestingly only 3
of these 34 SNPs were the reported genome-wide significant SNPs
(ZCWPW1/rs1476679, score = 1f; ABCA7/rs3764650, score = 2b;
and CLU/rs1532278, score = 2b), one was a reported suggestive
SNP (HRK/RNFT2/rs17429217, score = 2b), and the remaining
30 were in LD (r2$0.80) with the 44 lead SNPs reported in LOAD
GWA studies [5–9]. Table 4 summarizes LD between regulatory
SNPs with RegulomeDB score of ,3 and published GWAS SNPs.
Only one of the 34 SNPs had a score of 1b, while 18 had a score of
1f, 4 returned a score of 2a, and 11 a score of 2b.
A total of 10 confirmed loci and 3 suggestive loci harbored SNPs
with a RegulomeDB score ,3. The SNP with the most evidence
for regulatory function was rs667897 with a RegulomeDB score of
1b. This SNP is an intergenic SNP located in the MS4A region,
just downstream of MS4A6A. Nine other SNPs in the MS4A region
(of the 157 SNPs tested in this region) also had scores of less than 3,
as well as 20 SNPs in 9 other confirmed LOAD risk loci:
ZCWPW1 (1 of 8 SNPs tested), CLU (2 of 10 SNPs tested), ABCA7
(2 of 7 SNPs tested), CELF1 (8 of 25 SNPs tested), PTK2B (2 of 6
SNPs tested), CASS4 (1 of 11 SNPs tested), PICALM (2 of 93 SNPs
tested), CD2AP (1 of 69 SNPs tested), and BIN1 (1 of 6 SNPs
tested). Remarkably, eight SNPs in the CELF1 gene region on
chromosome 11 (SLC39A13/rs2293576, CELF1/rs7933019,
NDUFS3/rs2280231, MTCH2/rs7120548, NUP160/rs7114011,
CELF1/rs11039290, CELF1/rs6485758, and RAPSN/rs7103835)
with scores of 1f are in LD with the genome-wide significant
CELF1/rs10838725 SNP which by itself is not functional
according to RegulomeDB (score = 6). All eight are eQTLs for
C1QTNF4, and three of them (SLC39A13/rs2293576, MTCH2/
rs7120548, and NUP160/rs7114011) also affect expression of
MYBPC3 and SPI1. Three other suggestive novel loci, ADAMTS9,
ZNF592/ALPK3/SLC28A1, and HRK/RNFT2, also had variants
with strong evidence for regulatory function with scores of 2b (1 of
6 SNPs tested), 1f (2 of 7 SNPs tested), and 2b (1 of 1 SNP tested),
respectively.
Of the 30 SNPs that were in LD with reported genome-wide
significant variants and had high evidence of regulatory function,
10 were located in the MS4A region, including the SNP with the
most evidence for regulatory function, rs667897 (RegulomeDB
score = 1b). RegulomeDB cites rs667897 affects binding of 21
different proteins including BRCA1, SMARCC2, FOXA1, JUN,
and POLR2A and falls within both TCF11:MafG and NFE2L2
binding motifs. Six other SNPs in the MS4A region, including 5
intergenic (rs1303615, rs617135, rs11230180, rs2123314, and
rs655231) and 1 intronic (MS4A4E/rs2081547) SNPs, had
RegulomeDB scores of 1f, and similar to the top hit rs667897,
all are eQTLs for MS4A4A as evidenced by work in monocytes.
Some of the protein binding affected by these SNPs include
CEBPB, JUN, JUND, POLR2A, and SMARCC2. These are the
same proteins that are also affected by top MS4A region hit,
rs667897, however, motifs containing these variants have yet to be
determined. Three more SNPs in the MS4A region, rs636317,
rs636341, and rs7933202 were likely to affect binding according to
RegulomeDB (score = 2a, 2a, and 2b, respectively).
The reported ZCWPW1/rs1476679 SNP (RegulomeDB
score = 1f) is an eQTL for GATS, PILRB, and TRIM4, and similar
to other functional variants in our dataset, affects binding of
Table 1. Number of SNPs in linkage disequilibrium for all
published GWAS SNPs for HapMap3 and 1000 Genomes
populations at tested r2 thresholds.
Linkage Disequilibrium (r2) Threshold
0.80 0.90 1.0
1000 Genomes 612 466 189
Hap Map 3 122 85 62
TOTAL (overlaps removed) 614 472 191
doi:10.1371/journal.pone.0095152.t001
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RFX3, as well as CTCF. Two intronic CLU SNPs, rs1532278 and
rs867230, show evidence of regulatory function (RegulomeDB
score = 2b, each). The genome-wide significant CLU/rs1532278
SNP, located in intron 3 of CLU affects binding of NANOG,
TAF1, USF1, MAX, USF2, and GATA2 and is situated in the
Nkx2-5 binding motif. The second CLU/rs867230 variant, located
in the first intron of CLU, affects binding of GATA1 and GABPA
and alters the MEF-2 and Zfp740 motifs.
A genome-wide significant ABCA7/rs3764650 SNP (Regulo-
meDB score = 2a), has indications for binding six different proteins
(SP1, HNF4A, HNF4G, BHLHE40, USF1, and USF2) and is
located in the binding motifs for TBX22, TBX18, TBX15,
HNF4alpha1, COUPTF, HNF4, COUP-TF = HNF-4, NR2F1.
Another ABCA7/rs4147911 SNP (RegulomeDB score = 2b) affects
binding of IKZF1.
An eQTL for both DPYSL2 and PTK2B, rs17057043 (Reg-
ulomeDB score = 1f) is located in intron 5 of PTK2B, which is part
of the N-Myc and RBP-Jkappa binding motifs, and affects binding
of IRF1. PTK2B/rs73223431 SNP, also located in intron 5 of
PTK2B, has a score of 2b. Similar to ABCA7/rs3764650
(RegulomeDB score = 2b), PTK2B/rs73223431 falls in binding
motifs of TBX22, TBX15, and TBX18, among others.
Discussion
As the list of associated LOAD risk loci continues to grow, it
becomes increasingly important to decipher the biological
underpinnings of these associations. If we accept that these
associations are real, we must endeavor to explain them. Since
many of these risk variants are non-coding, one logical explanation
for their association is an effect on gene expression. The
ENCODE project has provided invaluable contributions to this
area of research with a wealth of data that is publicly available for
interpretation and expansion. These data are ideal for generating
hypotheses and furthering our understanding of gene expression
and epistasis. Here we have used two publicly available
bioinformatics tools, SNAP tool and RegulomeDB, to investigate
potential regulatory functions of non-APOE SNPs implicated with
risk and AAO of LOAD.
Of the 21 non-APOE genome-wide significant risk loci, ten—
ZCWPW1, CLU, ABCA7, MS4A4A/MS4A6E, PICALM, CD2AP,
BIN1, CELF1, CASS4, and PTK2B—had SNPs with functional
evidence. Of the 16 suggestive novel loci, three-- HRK/RNFT2,
ADAMTS9, and ZNF592/ALPK3/SLC28A1-- had SNPs with
functional evidence. Importantly, only three of the 34 SNPs with
evidence for potential regulatory function based on RegulomeDB
score were the reported genome-wide significant SNPs
[ZCWPW1/rs1476679 (score = 1f), CLU/rs1532278 (score = 2b),
and ABCA7/rs3764650 (score = 2b)] and one was a reported
suggestive SNP [HRK/RNFT2/rs17429217 (score = 2b)]. All three
reported genome-wide significant SNPs are intronic and our
findings suggest that they, rather than the SNPs in LD with them,
are causative for LOAD risk via a regulatory mechanism.
None of the ten MS4A region SNPs with a score of ,3 are
reported GWAS SNPs, indicating the difficulty of differentiating
between a true signal and a tag signal in association studies, as well
as highlighting the complexity of interactions between genetic
variants and disease risk. Of the remaining 24 putative regulatory
variants representing 12 loci other than the MS4A region, we
observe some thought-provoking outcomes. For example, synon-
ymous variant SLC39A13/rs2293576 (in LD with CELF1/
rs10838725, r2$0.8) is unique in this dataset because it is the
only SNP with regulatory evidence that resides in an exon,
reminding us that regulatory elements can be found within coding
sequences as well as in intergenic regions and introns. Further-
more, eight putative regulatory variants located in six different
genes (including the synonymous SLC39A13/rs2293576 variant)
are in LD with the reported CELF1/rs10838725 SNP, and all are
Table 2. RegulomeDB category summaries [2].
Category Description
Likely to affect binding and linked to expression of a gene target
1a eQTL + TF binding + matched TF motif + matched DNase footprint + DNase peak
1b eQTL + TF binding + any motif + DNase footprint + DNase peak
1c eQTL + TF binding + matched TF motif + DNase peak
1d eQTL + TF binding + any motif + DNase peak
1e eQTL + TF binding + matched TF motif
1f eQTL + TF binding/DNase peak
Likely to affect binding
2a TF binding + matched TF motif + matched DNase footprint + DNase peak
2b TF binding + any motif + DNase footprint + DNase peak
2c TF binding + matched TF motif + DNase peak
Less likely to affect binding
3a TF binding + any motif + DNase peak
3b TF binding + matched TF motif
Minimal binding evidence
4 TF binding + DNase peak
5 TF binding or DNase peak
6 Motif hit
doi:10.1371/journal.pone.0095152.t002
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Table 3. Details of study SNPS with putative regulatory function (RegulomeDB Score ,3).
Coordinate dbSNP ID RegulomeDB Gene/Locus Position* eQTL Motifs Protein
(0-based) Score (per dbSNP) Binding
chr11:59936978 rs667897 1b MS4A region intergenic MS4A4A TCF11:MafG SMARCC2
downstream MS4A6 NFE2L2 STAT1
downstream MS4A2 JUN
MXI1
YY1
CEBPB
GTF2F1
FOXA1
FOS
USF1
STAT3
BRCA1
EP300
POLR2A
ELK4
PRDM1
RFX5
GATA2
TRIM28
SETDB1
JUND
chr11:47461692 rs7103835 1f RAPSN intron 4 C1QTNF4
chr11:47530023 rs6485758 1f CELF1 intron 1 C1QTNF4
chr11:47572278 rs11039290 1f CELF1 intron 1 C1QTNF4 Glis2
Mtf1
chr11:47434985 rs2293576 1f SLC39A13 exon 5 C1QTNF4 RAD21
MYBPC3
Coordinate dbSNP ID RegulomeDB Gene/Locus Position* eQTL Motifs Protein
(0-based) Score (per dbSNP) Binding
SPI1
chr11:47509136 rs7933019 1f CELF1 intron 2 C1QTNF4
chr11:47600437 rs2280231 1f NDUFS3 59 UTR C1QTNF4 BCLAF1
CHD2
CREBBP
CTBP2
E2F1
E2F4
EFL1
ELK4
EP300
ERG
ETS1
EWSR1
FLI1
GABPA
GATA1
GTF2F1
HNF4A
IRF1
Data Integration of Regulatory Variants for Alzheimer’s Disease
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IRF4
JUNB
JUND
MYC
NFKB1
NR2C2
PAX5
POLR2A
SIX5
Coordinate dbSNP ID RegulomeDB Gene/Locus Position* eQTL Motifs Protein
(0-based) Score (per dbSNP) Binding
SMARCB1
SMARCC1
SP1
STAT1
TAF1
TBP
TCF4
TRIM28
USF1
WRNIP1
ZBTB7A
ZEB1
chr11:47662931 rs7120548 1f MTCH2 intron 1 C1QTNF4
MYBPC3
SPI1
chr11:47811308 rs7114011 1f NUP160 intron 29 C1QTNF4 AP-3
MYBPC3 Oct-1
SPI1 Irx-3
chr7:100004445 rs1476679 1f ZCWPW1 intron 11 GATS RFX3
PILRB CTCF
TRIM4
chr8:27220309 rs17057043 1f PTK2B intron 5 DPYSL2 N-Myc IRF1
PTK2B RBP-Jkappa
chr11:59885119 rs1303615 1f MS4A region intergenic MS4A4A
downstream of MS4A2
downstream MS4A6A
chr11:59936756 rs617135 1f MS4A region intergenic MS4A4A POLR2A
downstream MS4A6A MAX
Coordinate dbSNP ID RegulomeDB Gene/Locus Position* eQTL Motifs Protein
(0-based) Score (per dbSNP) Binding
SMARCC2
chr11:59961485 rs11230180 1f MS4A region intergenic MS4A4A JUNB
upstream MS4A6A NKB1
downstream MS4A4E
chr11:59966294 rs2123314 1f MS4A region intergenic MS4A4A
upstream MS4A6A
downstream MS4A4E
chr11:59989429 rs2081547 1f MS4A4E intron 2 MS4A4A CEBPB
JUN
JUND
chr11:60013856 rs655231 1f MS4A region intergenic MS4A4A RFX3
upstream MS4A4E
Data Integration of Regulatory Variants for Alzheimer’s Disease
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upstream MS4A4A
chr15:85425096 rs12917429 1f SLC28A1 intergenic NMB
upstream SLC28A1
chr15:85429355 rs12909280 1f SLC28A1 intron 1 NMB RFX3
chr11:60019149 rs636317 2a MS4A region intergenic ------- TAL1 CTCF
upstream MS4A4E CTCF RAD21
upstream MS4A4A FOXA1
SMC3
BCLAF1
YY1
POU2F2
ZNF143
chr11:60019160 rs636341 2a MS4A region intergenic ------- CTCF CTCF
upstream MS4A4E STAT1:STAT1 RAD21
upstream MS4A4A C/EBPbeta FOXA1
SMC3
Coordinate dbSNP ID RegulomeDB Gene/Locus Position* eQTL Motifs Protein
(0-based) Score (per dbSNP) Binding
BCLAF1
YY1
POU2F2
ZNF143
chr11:85815029 rs1237999 2a PICALM region intergenic ------- AP-1 JUN
upstream PICALM Jundm2 JUNB
JUND
FOS
chr19:1046519 rs3764650 2a ABCA7 intron 13 ------- TBX22 SP1
TBX18 HNF4A
TBX15 HNF4G
HNF4alpha1 BHLHE40
COUPTF USF1
HNF4 USF2
COUP-TF =HNF-4
NR2F1
chr12:117295332 rs17429217 2b HRK/RNFT2 region intergenic ------- HNF4 =COUP EBF1
downstream RNFT Hnf4a
downstream HRK
chr6:47447040 rs4715019 2b CD2AP intron 1 ------- Irx-3 POLR2A
Sox15
HoxB5
Zfp105
Hoxa3
DIx1
Hoxb8
Irx6
Hoxa6
Coordinate dbSNP ID RegulomeDB Gene/Locus Position* eQTL Motifs Protein
(0-based) Score (per dbSNP) Binding
Hoxb6
Hoxb5
chr8:27466314 rs1532278 2b CLU intron 3 ------- Nkx2-5 NANOG
TAF1
USF1
Data Integration of Regulatory Variants for Alzheimer’s Disease
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MAX
USF2
GATA2
chr11:59936925 rs7933202 2b MS4A region intergenic ------- DMRT3 POLR2A
downstream MS4A6A SMARCC2
STAT1
JUN
YY1
CEBPB
GTF2F1
FOS
USF1
STAT3
EP300
ELK4
MXI1
FOXA1
BRCA1
PRDM1
GATA2
TRIM28
SETDB1
JUND
chr11:85811237 rs542126 2b PICALM region intergenic ------- E47 HNF4A
Coordinate dbSNP ID RegulomeDB Gene/Locus Position* eQTL Motifs Protein
(0-based) Score (per dbSNP) Binding
upstream PICALM RXRA
POLR3A
USF2
USF1
chr19:1047686 rs4147911 2b ABCA7 intron 16 ------- HEN1 IKZF1
chr20:54997567 rs6024870 2b CASS4 intron 2 ------- Pax-3 TCF4
CTCF
FOS
RAD21
chr2:127888336 rs11689287 2b BIN1 region intergenic ------- FOXL1 CTCF
upstream BIN1 Oct-1
Six6
FOXP1
Tbp
chr3:64918621 rs812651 2b ADAMTS9-AS2 intron 4 ------- RBP-Jkappa HNF4A
SETDB1
chr8:27219986 rs73223431 2b PTK2B intron 5 ------- TRUE MYC
TBX15 GATA1
TBX18 CDX2
TBX22 POLR2A
T JUN
Brachyury NKFB1
HNF4A
GATA2
chr8:27468502 rs867230 2b CLU intron 1 ------- MEF-2 GATA1
Zfp740 GABPA
Bolded SNPs are published GWAS SNPs.
*Upstream/downstream designation based upon gene direction per NCBI.
doi:10.1371/journal.pone.0095152.t003
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eQTLs for C1QTNF4. These results suggest future work should
examine C1QTNF4 (aka CTRP4) as a potential player in LOAD
risk in addition to currently implicated CELF1 gene. C1QTNF4 is
an inflammatory cytokine capable of activating both Stat3/IL6
and NF-kB pathways, as shown in cancer cells [13]. The
implication of the inflammatory pathway in AD pathogenesis
and the inverse association between AD and cancer may explain in
part the observed relationship between these SNPs and their effect
on C1QTNF4 expression [14], [15].
According to RegulomeDB, the binding of the IKAROS family
zinc finger 1 (Ikaros) transcription factor, IKZF1, is affected by
ABCA7/rs4147911 (score = 2b). It is worth noting that the
expression of another LOAD risk gene, INPP5D, is regulated by
the Ikaros transcription factor family in B cells [16], suggesting a
potential functional link between ABCA7 and INPP5D. Similarly,
RegulomeDB findings suggest other proteins whose binding seems
to be affected by variants at different LOAD loci (Table 3).
Another position of interest is intron 5 of PTK2B. Two variants in
Table 4. Linkage disequilibrium for published GWAS SNPs with functional proxies (RegulomeDB score ,3) according to SNAP
search.
GWAS SNP Functional Proxy SNP RegulomeDB Score
ABCA7/rs3764650 ABCA7/rs3764650*** 2a
ABCA7/rs4147911** 2b
HRK/RNFT2/rs17429217 HRK/RNFT2/rs17429217*** 2b
ADAMTS9/rs704454 ADAMTS9-AS2/rs812651** 2b
CASS4/rs7274581 CASS4/rs6024870* 2b
ZCWPW1/rs1476679 ZCWPW1/rs1476679*** 1f
CD2AP/rs9296559 CD2AP/rs4715019*** 2b
CD2AP/rs9349407 CD2AP/rs4715019*** 2b
CELF1/rs10838725 SLC39A13/rs2293576* 1f
CELF1/rs7933019** 1f
NDUFS3/rs2280231** 1f
MTCH2/rs7120548* 1f
NUP160/rs7114011** 1f
CELF1/rs11039290** 1f
CELF1/rs6485758** 1f
RAPSN/rs7103835* 1f
PTK2B/rs28834970 PTK2B/rs17057043* 1f
PTK2B/rs73223431* 2b
CLU/rs1532278 CLU/rs1532278*** 2b
CLU/rs867230* 2b
PICALM/rs561655 PICALM/rs1237999* 2a
PICALM/rs542126* 2b
ZNF592/ALPK3/SLC28A1/rs3743162 SLC28A1/rs12917429*** 1f
SLC28A1/rs12909280*** 1f
BIN1/rs7561528 BIN1/rs11689287** 2b
GWAS SNP Functional Proxy SNP RegulomeDB Score
MS4A4A/rs4938933 MS4A region/rs11230180* 1f
MS4A region/rs2123314* 1f
MS4A4E/rs2081547* 1f
MS4Aregion/rs655231** 1f
MS4A region/rs636341** 2a
MS4A region/rs636317** 2a
MS4A region/rs7933202* 2b
MS4A6A/rs610932 MS4A region/rs7933202* 2b
MS4A region/rs667897* 1b
MS4A region/rs1303615* 1f
MS4A region/rs617135* 1f
Linkage disequilibrium (r2) values are indicated as—*$0.80, **$0.90, and *** = 1.0.
Bolded SNPs are GWAS SNPs with regulatory function.
doi:10.1371/journal.pone.0095152.t004
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this intron had RegulomeDB scores less than 3 (rs17057043,
score = 1f and rs73223431, score = 2b), suggesting that intron 5 of
PTK2B may play an important role in affecting the binding of
regulatory proteins and consequently the risk of LOAD.
Variants in reported suggestive novel loci for AAO of AD,
ZNF592/ALPK3/SLC28A1, HRK/RNFT2, and ADAMTS9, are
also of functional importance as reflected by RegulomeDB scores
of 1f, 2b, and 2b, respectively. Both rs12917429 and rs12909280
in the SLC28A1 region are eQTLs for neuromedin B (NMB), with the
latter SNP suggested to affect binding of RFX3. According to
GeneCards [17] NMB is a ligand that binds to bombesin receptors
to instigate smooth muscle contractions. The bombesin peptides
and receptors have been implicated in a variety of cellular
processes and are frequently overexpressed in cancer cells [18],
[19]. RFX3 has been shown to be responsible for proper Corpus
Callosum development in mice [20]. RFX3 also affects expression
of glucokinase and subsequently affects differentiation and
function of beta cells [21]. Two other SNPs with RegulomeDB
scores of 1f, ZCWPW1/rs1476679 and rs655231 (MS4A region),
show indications for affecting binding of RFX3 in K562 (chronic
myelogenous leukemia, CML) cells. Given the proposed link
between insulin resistance and AD as a result of insulin degrading
enzyme (IDE), RFX3 may be an interesting transcription factor to
examine in the context of LOAD pathogenesis [22].
Although RegulomeDB is an extensive database for the
annotation of variants’ effects on gene expression, it provides
information for only selected DNA binding elements in certain cell
types. A total of 220 variants of the 614 we examined returned
scores of ‘‘No data,’’ meaning we cannot argue against their
involvement in gene expression as related to LOAD pathogenesis.
Along the same lines, some loci have a markedly higher number of
SNPs that have been tested for expression effects than others.
Thus, we make no assumptions that the mere number of putative
regulatory variants for a given locus is indicative of the magnitude
of that locus’ role in risk and disease process. Moreover, the
primary focus of our study was RegulomeDB and prediction of
regulatory effects on gene expression based on the data included in
that database. Therefore some other regulatory mechanisms, such
as regulation of RNA splicing, or prediction of changes in protein
structure and/or function were not covered as part of this study.
In conclusion, these results highlight a number of important
considerations for the interpretation of future GWAS data
including the necessity of carefully examining LD structure for
SNPs showing association with disease risk. Additionally, careful
attention should be paid to the regulatory function of associated
SNPs and those in LD with such SNPs to clarify correlation
between disease and associated variants and better understand
complex disease mechanisms. These factors will be critical for
elucidating genetic mechanisms that are truly causal for LOAD.
Although the cellular pathology of the disease appears to be more
widely agreed upon, the molecular basis is still elusive, requiring
resolution before pathogenesis is completely comprehended.
Identification of potential therapeutic targets can be expedited
with a more extensive molecular understanding of the disease
process. Given the replication of association of loci with unclear or
unknown functions with LOAD risk, future studies should aim to
determine their functions both in normal and disease states to
identify their roles in disease pathogenesis.
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